Talis Biomedical Corporation
TLIS Healthcare Medical Devices
Talis Biomedical Corporation’s revenue for fiscal 2023 (year ended December 2023) was $2.1 million, down 55.7% from fiscal 2022. Operating cash flow growth for three consecutive years.
Follow TLIS
Talis Biomedical Corporation (TLIS) EV/Sales
As of 1 April 2026, Talis Biomedical Corporation (TLIS) trades at a EV/Sales of −55.3×. Over the past ten years it has ranged from −58.2× (July 2025) to −1.7× (July 2021); the current reading is higher than 32% of that period. That is below the Medical Devices industry median of 2.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2023 | −29.1× | — |
| FY2022 | −24.3× | — |
| FY2021 | −17.3× | — |
| FY2020 | −10.4× | — |
| FY2019 | −10.4× | — |
| FY2018 | −10.4× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2024 | −55.5× | — |
| Dec 2023 | −29.1× | — |
| Sep 2023 | −35.2× | — |
| Jun 2023 | −30.2× | — |
| 14 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| TLIS Talis Biomedical Corporation | −55.3× |
| XTNT Xtant Medical Holdings, Inc. compare | 0.5× |
| RPID Rapid Micro Biosystems, Inc. compare | 1.0× |
| TELA TELA Bio, Inc. compare | 1.1× |
| MYO Myomo, Inc. compare | 1.2× |
| SNWV Sanuwave Health Inc. compare | 1.2× |
| SRTS Sensus Healthcare, Inc. compare | 2.1× |
| MDAI Spectral AI, Inc. compare | 3.0× |
| COCH Envoy Medical, Inc. compare | 390× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)